Table 3. Clinical evaluation parameters for quality of life.
| Variables | MP group (n=35) | HP group (n=35) | Overall | MP group | HP group | |||||||
| Mean±SD | Mean | 95% CI | Effect size(d) |
Mean±SD | Mean | 95% CI | Effect size(d) |
p | p | p | p | |
| SF-36PF | ||||||||||||
| Baseline | 49.6±22.1 | 40.4±20.3 | 0.067 | |||||||||
| End of treatment | 63.4±23.5 | -13.81 | -16.9 to -7.08 | -0.85 | 52.3±21.5 | -11.91 | -16. to -5.1 | -0.66 | 0.072 | 0.144 | <0.001*** | <0.001*** |
| 1st month | 69.7±21.7 | -20.13 | -23.5 to -11.3 | -0.99 | 55±23.8 | -14.57 | to -7.7 | -0.84 | 0.011* | <0.001*** | <0.001*** | |
| SF-36PR | ||||||||||||
| Baseline | 22.1±32.5 | 18.6±31.1 | 0.640 | |||||||||
| End of treatment | 44.9±41.2 | -22.71 | -35.1 to -7.74 | -0.54 | 28.1±43.0 | -9.55 | to 4.92 | -0.20 | 0.112 | 0.581 | 0.003** | 0.2374 |
| 1st month | 51.5±42.8 | -29.38 | -42.9 to -9.90 | -0.55 | 34.4±42.0 | -15.81 | -28. to 2.64 | -0.28 | 0.108 | 0.002** | 0.101 | |
| SF-36BP | ||||||||||||
| Baseline | 38.6±14.9 | 34.9±16.4 | 0.295 | |||||||||
| End of treatment | 60.6±20.6 | -21.99 | -27.1 to -14.6 | -1.17 | 54.1±17.0 | -19.23 | -21. to -11.0 | -1.14 | 0.130 | 0.138 | <0.001*** | <0.001*** |
| 1st month | 63.3±20.6 | -24.7 | -30.1 to -15.9 | -1.13 | 54.1±16.5 | -19.17 | -21. to -11.0 | -1.05 | 0.088 | <0.001*** | <0.001*** | |
| SF-36GH | ||||||||||||
| Baseline | 46.1±21.0 | 40.7±16.4 | 0.233 | |||||||||
| End of treatment | 52.8±20.5 | -6.65 | -10.6 to -0.23 | -0.36 | 45.9±21.5 | -5.23 | -7.0 to 2.16 | -0.18 | 0.190 | <0.001*** | 0.04* | 0.289 |
| 1st month | 52.3±21.9 | -6.13 | -10.0 to 1.218 | -0.27 | 41.7±20.5 | -1.01 | -19. to 4.92 | -0.20 | 0.049* | 0.237 | 0.120 | |
| SF-36VE | ||||||||||||
| Baseline | 49.3±23.5 | 41.3±18.5 | 0.105 | |||||||||
| End of treatment | 56.0±25.9 | -6.74 | -11.9 to 0.824 | -0.30 | 49.4±20.6 | -8.09 | -9.3 to -0.3 | -0.37 | 0.207 | <0.001*** | 0.085 | 0.032* |
| 1st month | 60.5±22.6 | -11.16 | -15.6 to -0.94 | -0.39 | 50±21.1 | -8.71 | -6.4 to 4.47 | -0.06 | 0.045* | 0.028* | 0.7128 | |
| SF-36SF | ||||||||||||
| Baseline | 53.9±23.6 | 51.7±24.2 | 0.701 | |||||||||
| End of treatment | 69.3±22.5 | -15.4 | -20.4 to -7.86 | -0.78 | 65.1±21.4 | -13.43 | -10. to -2.1 | -0.52 | 0.442 | 0.821 | <0.001*** | 0.004** |
| 1st month | 74.0±21.5 | -20.17 | -20.4 to -7.86 | -0.78 | 70.9±19.1 | -19.25 | -13. to -0.9 | -0.40 | 0.538 | <0.001*** | 0.024* | |
| SF-36ER | ||||||||||||
| Baseline | 26.7±37.8 | 20.9±33.5 | 0.554 | |||||||||
| End of treatment | 46.1±43.5 | -19.4 | -9.79 to -1.62 | -0.48 | 43.8±44.4 | -22.81 | -18. to -4.3 | -0.55 | 0.791 | 0.702 | 0.007** | 0.002** |
| 1st month | 53.6±44.1 | -26.89 | -10.7 to -1.12 | -0.42 | 58.3±44.8 | -37.4 | -18. to -4.3 | -0.55 | 0.645 | 0.017* | 0.002** | |
| SF-36MH | ||||||||||||
| Baseline | 61.8±19.2 | 52.3±19.9 | 0.046* | |||||||||
| End of treatment | 68.5±19.4 | -6.64 | -30.9 to -5.25 | -0.49 | 59.6±21.9 | -7.28 | -9.7 to -0.9 | -0.42 | 0.088 | <0.001*** | 0.007** | 0.018* |
| 1st month | 70.4±19.1 | -8.59 | -38.4 to -9.23 | -0.56 | 62.5±18.5 | -10.16 | -13. to -2.6 | -0.51 | 0.095 | 0.002** | 0.004** | |
| MP: Mud pack; HP: Hot pack; SD: Standard deviation; CI: Confidence interval; SF-36PF: Short form-36 physical functioning; SF-36PR: Short form-36 physical role; SP-36BP: Short form-36 bodily pain; SF-36GH: Short form 36 general health; SF-36VE: Short form 36 Vitality/Energy; SF-36SF: Short form 36 social functioning; SF-36ER: Short form 36 emotional role; SF-36MH: Short form 36 mental health; * p<0.05; ** p<0.01; *** p<0.001. | ||||||||||||